(MENAFN- GlobeNewsWire - Nasdaq) Capitalize on demand for automated, high-throughput and single-cell solutions, driven by personalized medicine, proteomics, genomics and biopharma researchDublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering.
The global cell lysis and cell fractionation market was valued at US$2.8 billion in 2025 and is projected to reach US$4.5 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7% over the forecast period. Market growth is being supported by advances in biotechnology, rising investment in life sciences research, expanding proteomics and genomics applications, and increasing demand for personalized medicine.
Cell lysis and fractionation technologies are integral to genomics, proteomics, metabolomics, drug discovery, clinical diagnostics and biopharmaceutical production. Their performance directly influences the yield, purity and integrity of proteins, nucleic acids, organelles and other cellular components used in downstream analysis. As research workflows become more complex, laboratories and biopharmaceutical companies are prioritizing precise, reproducible and scalable solutions.
Market Trends and Growth Drivers
Demand for advanced cell lysis systems is increasing as researchers require higher sample throughput, improved reproducibility and better preservation of sensitive biomolecules. Mechanical, chemical and enzymatic methods continue to serve a broad range of sample types, while automated platforms are reducing processing time, human error and variability across large experimental workflows.
Technological innovation is also reshaping cell fractionation. Advances in ultracentrifugation, density-gradient separation and microfluidics are enabling more precise isolation of nuclei, mitochondria, cytoplasmic material and other subcellular fractions. These capabilities are particularly important in cancer research, neurobiology, protein analysis and pharmaceutical development, where high-purity fractions support detailed investigation of disease pathways, therapeutic targets and drug mechanisms.
Emerging technologies such as electroporation, pressure cycling and microscale separation offer alternatives for sensitive samples and applications requiring reduced biomolecular damage. Microfluidic fractionation is also improving recovery and purity while limiting sample loss. These developments are expanding opportunities in single-cell analysis, where accurate handling of limited cellular material is essential.
Artificial intelligence and machine learning are expected to support further optimization by helping researchers model process conditions, predict fractionation outcomes and improve workflow consistency. The integration of automation, advanced analytics and high-throughput processing is strengthening the role of cell lysis and fractionation in modern molecular biology.
Additional growth is being generated by the biopharmaceutical industry's focus on targeted therapies for cancer, neurodegenerative disorders and other complex diseases. Regulatory requirements for biologics manufacturing and quality control are also encouraging adoption of robust, validated processing solutions. Meanwhile, increasing demand for precise treatment strategies is reinforcing the need for detailed molecular and cellular data.
Report Scope
The report analyzes the global cell lysis and cell fractionation market in terms of market value in U.S. dollars. It provides annual sales analysis and forecasts for the period from 2025 through 2032.
By component: Consumables and instruments. By cell type: Mammalian cells, microbial cells and other cell types. By end use: Research laboratories and institutes, pharmaceutical and biotechnology companies, and other end users. By geography: United States, Canada, Japan, China, Europe, Asia-Pacific and the Rest of World. European coverage includes France, Germany, Italy, the United Kingdom and the Rest of Europe.
Key Market Insights
The consumables segment is forecast to reach US$2.8 billion by 2032, advancing at a CAGR of 8.1%. The instruments segment is projected to expand at a CAGR of 5.5% during the analysis period. The U.S. cell lysis and cell fractionation market was valued at US$823 million in 2025. China is forecast to grow at a CAGR of 6.7% and reach US$799.6 million by 2032. Japan, Canada, Germany and the broader Asia-Pacific region are also expected to present significant growth opportunities.
Strategic Value of the Report
Comprehensive analysis of the global cell lysis and cell fractionation market across major segments and geographic regions. Assessment of market trends, growth drivers, restraints and emerging technology developments. Competitive intelligence covering the market presence and prospects of leading participants. Actionable insights designed to support strategic planning, investment assessment and revenue opportunity identification. Independent annual sales data and market forecasts presented in US$ millions. One year of complimentary updates covering relevant market developments.
Key Questions Addressed
How will the global cell lysis and cell fractionation market evolve through 2032? Which factors are driving or limiting market expansion? Which product, cell type and end-use segments offer the strongest growth potential? How will regional and segment-level market positions change during the forecast period? Which companies are shaping the competitive landscape, and what are their growth prospects?
Companies Featured
Beckman Coulter, Inc. Becton, Dickinson and Company Bio-Rad Laboratories, Inc. Cell Signaling Technology, Inc. F. Hoffmann-La Roche AG Merck KGaA Miltenyi Biotec GmbH QIAGEN N.V. Qsonica, LLC Thermo Fisher Scientific, Inc.
Domain Expert Insights
The report incorporates perspectives from domain experts across industry, enterprise and academia, providing context beyond conventional published research. The report tracks early market signals emerging from expert discussions, corporate activity, conference sessions, keynote presentations, panel discussions, institutional publications, company disclosures, annual reports and other validated sources.
These insights connect developing signals with broader strategic market direction, helping identify where the market is moving, which forces are driving change and which developments may have the greatest commercial impact. The analysis also extends beyond market-level findings to examine companies participating in and influencing the competitive environment.
Where analytically relevant, market share is evaluated at both global and regional levels. This approach reflects the significant differences that can exist among geographic markets and provides detail aligned with the competitive structure, maturity and dynamics of each region.
Key Attributes
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment